Study of QL2108 compared with Dupixent for atopic dermatitis
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests whether an experimental medication, QL2108, works as well as a standard treatment (Dupixent) for moderate-to-severe atopic dermatitis (eczema). It may help reduce the severity of eczema symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with atopic dermatitis (eczema) for at least 1 year.
- Your eczema covers a significant area of your body (at least 10% of body surface) and is considered moderate-to-severe based on trial scoring.
- You have not previously used or participated in a clinical trial with dupilumab (Dupixent) or similar targeted antibody treatments.
- You have not received a live vaccine (like measles, mumps, rubella, or nasal flu vaccine) within 12 weeks before starting the trial.
- You have not participated in any other investigational drug or device trial within 12 weeks or 5 half-lives before this trial begins.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new biologic medicine (IBI3027) works as well as an approved medicine (dupilumab) for treating moderate-to-severe eczema. If you join, you may receive one of the two treatments, and researchers will compare their effects on your skin and itching.
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
This study tests whether taking Dupixent and receiving narrowband UVB light can improve moderate to severe atopic dermatitis (eczema). It may help people whose symptoms are significant despite usual care.
This trial tests a new version of Dupixent® (called CKD-706) to see how it compares to the approved medicine in healthy adults. It's a first step to make sure the new medicine works similarly and is safe.
This study looks at whether children with well-controlled eczema can safely reduce how often they take Dupixent. It aims to find the lowest effective dose to keep eczema under control.
This trial studies how the body’s “molecular signals” change in the skin after using dupilumab for eczema. It may help researchers understand who benefits most from treatment.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.